Hyperuricaemia and gout in the Pacific
- PMID: 40069386
- DOI: 10.1038/s41584-025-01228-7
Hyperuricaemia and gout in the Pacific
Abstract
Gout is the most common form of inflammatory arthritis in adults worldwide. There has been a steady increase in prevalence, which varies across different geographic areas and is high in the Indigenous (First Nations) peoples of the Pacific region. Palaeo-archaeological studies demonstrate that gout was present in the Pacific region prior to European colonization, which is suggestive of genetic predisposition. Genetic risk factors, including population-specific genetic variants and genetic variants shared across populations, particularly those influencing urate transporters, have been identified in Indigenous peoples of the Pacific that partly explain the earlier age of onset of gout. Indigenous peoples of the Pacific experience severe gout, with frequent flares, high hospitalization rates and tophaceous gout, all aggravated by socio-cultural factors. Despite a specific need for effective gout management, Indigenous peoples of the Pacific are under-represented in gout research and inequities in care continue. Indigenous peoples-led, holistic gout management programmes are systematically and urgently required in this region, where gout is a major public health issue. Importantly, a foundation of cultural safety is necessary to underpin such programmes.
© 2025. Springer Nature Limited.
Conflict of interest statement
Competing interests: N.D. has received consulting fees, speaker fees or grants from Aristea, Arthrosi, AstraZeneca, Avalo, Biomarin, Dexcel Pharma, Hikma, Horizon, JPI, JW Pharmaceutical Corporation, LG Chem, Novartis, PK Med, Protalix, PTC Therapeutics, Selecta, Shanton Pharma, Sobi and Unlocked Labs. T.R.M. has received research funding and consulting fees from Variant Bio. L.K.S. has received research funding from the New Zealand Health Research Council and consulting fees from Pharmac outside the submitted work. T.P. has received research funding from Variant Bio and honorary and consulting fees from Horizon Pharmaceuticals and Novartis, unrelated to this work. B.G., M.L., T.B., L.T.K., S.O., S.V., A.L. and E.O. declare no competing interests.
References
-
- GBD 2021 Gout Collaborators. Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 6, e507–e517 (2024). - DOI
-
- Stamp, L. K., Christensen, R. & Morillon, M. B. Serum urate as a surrogate outcome for gout flares: where do we stand today? Gout Urate Cryst. Depos. Dis. 2, 70–76 (2024). - DOI
-
- Pascart, T. & Lioté, F. Gout: state of the art after a decade of developments. Rheumatology 58, 27–44 (2019). - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
